Vimarsana
Biggest News Aggregation in the World

Page 2 - Consensus Decision Pathway News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Consensus Decision Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Consensus Decision Pathway Today - Breaking & Trending Today

Don't Miss a Beat: ESC Heart Failure Association Preview - Vimarsana News

Don't Miss a Beat: ESC Heart Failure Association Preview

In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

Current Practice Standard for Patients with Pretreated Hypercholesterolemia - Vimarsana News

Current Practice Standard for Patients with Pretreated Hypercholesterolemia

Dr Michos offers strategies to successfully reduce LDL levels in patients with cardiovascular disease.

Source: ajmc.com
Non-Statin Therapies for Patients at High Risk for Cardiovascular Disease - Vimarsana News

Non-Statin Therapies for Patients at High Risk for Cardiovascular Disease

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.

Source: ajmc.com
Novartis Entresto receives positive CHMP opinion for pediatric heart failure - Vimarsana News

Novartis Entresto receives positive CHMP opinion for pediatric heart failure

If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric... | March 31, 2023

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Entresto receives positive CHMP opinion for pediatric heart failure - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Entresto receives positive CHMP opinion for pediatric heart failure

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Entresto receives positive CHMP opinion for pediatric heart failure